STRATA Skin Sciences Files 8-K Report
Ticker: SSKN · Form: 8-K · Filed: Jul 11, 2024 · CIK: 1051514
| Field | Detail |
|---|---|
| Company | Strata Skin Sciences, Inc. (SSKN) |
| Form Type | 8-K |
| Filed Date | Jul 11, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $8.0 million, $8.4 million, $6.8 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, financial-reporting, company-update
TL;DR
STRATA Skin Sciences dropped an 8-K on July 11th – check it for financial and operational updates.
AI Summary
On July 11, 2024, STRATA Skin Sciences, Inc. filed an 8-K report detailing significant events. The filing includes information on the company's results of operations and financial condition, as well as disclosures under Regulation FD and other events. It also lists financial statements and exhibits.
Why It Matters
This 8-K filing provides crucial updates on STRATA Skin Sciences' financial performance and operational status, which are important for investors to assess the company's current health and future prospects.
Risk Assessment
Risk Level: low — This filing is a standard 8-K report and does not appear to contain any immediate negative news or significant risk factors.
Key Players & Entities
- STRATA Skin Sciences, Inc. (company) — Registrant
- July 11, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania 19044 (address) — Principal Executive Offices
- MELA SCIENCES, INC. (company) — Former Company Name
- ELECTRO OPTICAL SCIENCES INC (company) — Former Company Name
FAQ
What is the primary purpose of this 8-K filing for STRATA Skin Sciences, Inc.?
The primary purpose is to report on the company's results of operations and financial condition, Regulation FD disclosures, other events, and financial statements and exhibits as of July 11, 2024.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on July 11, 2024.
What is STRATA Skin Sciences, Inc.'s state of incorporation and principal executive office address?
STRATA Skin Sciences, Inc. is incorporated in Delaware and its principal executive offices are located at 5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania 19044.
What were STRATA Skin Sciences, Inc.'s former company names?
STRATA Skin Sciences, Inc.'s former company names were MELA SCIENCES, INC. and ELECTRO OPTICAL SCIENCES INC.
What standard industrial classification code is associated with STRATA Skin Sciences, Inc.?
The standard industrial classification code associated with STRATA Skin Sciences, Inc. is 3841, for SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
Filing Stats: 1,012 words · 4 min read · ~3 pages · Grade level 9.9 · Accepted 2024-07-11 08:00:44
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share SSKN The NASDAQ
- $8.0 million — eliminary total revenue in the range of $8.0 million - $8.4 million for the second quarter o
- $8.4 million — revenue in the range of $8.0 million - $8.4 million for the second quarter of 2024. Consist
- $6.8 million — quivalents, and restricted cash totaled $6.8 million at the end of the second quarter of 202
Filing Documents
- ef20032281_8k.htm (8-K) — 31KB
- ef20032281_ex99-1.htm (EX-99.1) — 10KB
- image0.jpg (GRAPHIC) — 194KB
- 0001140361-24-032885.txt ( ) — 664KB
- sskn-20240711.xsd (EX-101.SCH) — 4KB
- sskn-20240711_lab.xml (EX-101.LAB) — 21KB
- sskn-20240711_pre.xml (EX-101.PRE) — 16KB
- ef20032281_8k_htm.xml (XML) — 4KB
02
Item 2.02. Results of Operations and Financial Condition. On July 11, 2024, STRATA Skin Sciences, Inc. (the "Company") issued a press release announcing preliminary, unaudited results of operations for the second fiscal quarter of 2024. The full text of such press release is furnished as Exhibit 99.1 to this report. The information set forth under this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
01
Item 7.01. Regulation FD Disclosure. On July 11, 2024, STRATA Skin Sciences, Inc. (the "Company") issued a press release announcing preliminary, unaudited results of operations for the second fiscal quarter of 2024. The full text of such press release is furnished as Exhibit 99.1 to this report. The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
01
Item 8.01. Other Events. On July 11, 2024, the Company announced preliminary total revenue in the range of $8.0 million - $8.4 million for the second quarter of 2024. Consistent with the Company's stated plans of realigning its devices and removing them from underperforming accounts, the domestic installed base of XTRAC devices declined from 907 at the end of the first quarter of 2024 to 881 at the end of the second quarter of 2024. The domestic installed base of TheraClear X devices continued to grow, rising from 104 at the end of the first quarter of 2024 to 117 at the end of the second quarter of 2024. Cash, cash equivalents, and restricted cash totaled $6.8 million at the end of the second quarter of 2024. Safe Harbor Statement The information in this filing includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company's plans, objectives, expectations and intentions and may contain words such as "will," "may," "seeks," and "expects," that suggest future events or trends. Actual results may differ materially from the Company's expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions or supply chain interruptions resulting from the corona virus and political factors or conditions affecting the Company and the medical device industry in general, as well as more specific risks and uncertainties set forth in the Company's SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this current report are made as of the date of this current report, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urg
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. The following press release is furnished as an exhibit to this Current Report on Form 8-K pursuant to Item 2.02 and Item 7.01 and shall not be deemed to be "filed": 99.1 Press Release dated July 11, 2024 issued by STRATA Skin Sciences, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STRATA SKIN SCIENCES, INC. Date: July 11, 2024 By: /s/ Christopher Lesovitz Christopher Lesovitz Chief Financial Officer -3-